You H, et al. - Researchers examined the link between serum levels of soluble ST2 (sST2) and prognosis in pediatric dilated cardiomyopathy (PDCM). In this study, 94 patients with PDCM were examined who were admitted to two centers in China and were followed up for adverse events (death, cardiac transplantation, and heart failure-related rehospitalization). Assessments of BNP and sST2 levels were done. Findings revealed the occurrence of 28 (29.8%) adverse events over a median of 678 (IQR:533-785) days. An increased risk of short-term (< 6 months) and long-term adverse events (2 years) was observed among patients in the highest tertile of sST2 levels vs those in lower tertiles. An intermediate risk subgroup was recognized, which reported an adverse event in 24% of patients. In patients with PDCM, a link was evident between serum sST2 levels and adverse events. Serum sST2 levels displayed a strong prognostic ability in these patients. Patient management could be aided with serial measurements of sST2, in terms of monitoring outcomes of treatment.